McMaster University

Medical Sciences
Graduate Program

Scope of Search

Fiona Smaill

Fiona Smaill

MBCHB, MSc, FRACP, FRCP (C)
Professor

Research Interests

HIV infection; infections in immunocompromised hosts; diagnostic medical microbiology; infection control; infections in pregnancy; clinical epidemiology.

Dr. Smaill is actively involved in clinical trials in HIV management, the development of vaccines for tuberculosis, and management of infections in pregnancy. Her interest in HIV infection includes multicentre trials to evaluate efficacy and side-effects of different antiretroviral regimens and work on gender differences in the management of HIV infection. Dr. Smaill is also working with Dr. Xing on an adenovirus-based vaccine for tuberculosis and they are currently running a phase 1 clinical trial to evaluate their novel TB vaccine in healthy volunteers.

Dr. Smaill has an ongoing commitment to complete and update several Cochrane Systematic Reviews related to the management of infections in pregnancy, with a focus on treatment of asymptomatic bacteriuria and antibiotic prophylaxis for cesarean sections. She is an associate editor for ACP Evidence-Based Medicine. She is the co-editor of the recently published second edition of the textbook "Evidence-Based Infectious Diseases".


Education and Professional Standing

MSc Design, Measurement & Evaluation, McMaster University, 1997
FRCPC Medical Microbiology, 1988
FRCPC Infectious Diseases, 1987
FRCPC Internal Medicine, 1985
MBChB, Otago University (New Zealand) 1978

Team Members

Research Coordinators: Sarah Culgin and Laura Puri

Research Nurse: Marcia Stirling

Contact

McMaster University
Health Sciences Centre

telephone: (905) 521-2100 ext. 76332
email: smaill@mcmaster.ca

Program Area

Infection & Immunity

Research Focus

HIV Infection, Infectious Diseases, Diagnostic Microbiology, Meta-Analyses, Pregnancy

Selected Publications

  • New approaches to TB vaccination. Xing Z, Jeyanathan M, Smaill F. Chest. 2014 Sep;146(3):804-12. doi: 10.1378/chest.14-0439.
  • Human type 5 adenovirus-based tuberculosis vaccine: is the respiratory route of delivery the future? Smaill F, Xing Z. Expert Rev Vaccines. 2014 Aug;13(8):927-30. doi: 10.1586/14760584.2014.929947. Epub 2014 Jun 17.
  • A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Smaill F, Jeyanathan M, Smieja M, Medina MF, Thanthrige-Don N, Zganiacz A, Yin C, Heriazon A, Damjanovic D, Puri L, Hamid J, Xie F, Foley R, Bramson J, Gauldie J, Xing Z. Sci Transl Med. 2013 Oct 2;5(205):205ra134. doi: 10.1126/scitranslmed.3006843.